Cardiac Biomarkers are substances that are released into the blood when the heart is damaged or stressed. The global Cardiac Biomarkers market is expected to witness remarkable growth over the next few years. Factors such as the increasing patient population suffering from cardiovascular diseases and rising demand for diagnostic and testing of several cardiovascular diseases are anticipated to fuel the growth of the global Cardiac Biomarkers market over the forecast period. According to World Health Organization, cardiovascular diseases (CVDs) are the number 1 cause of death globally, taking an estimated 17.9 million lives each year. Four out of 5 CVD deaths are due to heart attacks and strokes, and one-third of these deaths occur prematurely in people under 70 years of age.
Similarly, other key aspects such as growth in the senior population and rising funding from public and private organizations for research and development on cardiac biomarkers are further enhancing the growth of the market in the coming years.
On the downside, factors such as the development of other methods for the diagnosis of cardiovascular diseases, the high cost of the procedure, and vast competition among existing players are projected to hamper the market’s development in the forthcoming years.
Cardiac Biomarkers Market Segment Overview
According to Type, the Troponins I and T is the fastest-growing segment in the Cardiac Biomarkers market. This is because of its extraordinary specificity and ability to accurately detect the cardiac events of Acute Coronary Syndrome (ACS). Additionally, based on application, Myocardial infarction (MI) holds the largest share in the market followed by Acute Coronary Syndrome (ACS) due to the highest prevalence rate among cardiovascular diseases (CVDs).
Cardiac Biomarkers Market Regional Overview
Region-wise, North America and Europe dominate the global Cardiac Biomarkers market. This can be attributed to the growing patient population suffering from cardiovascular diseases in these regions. Moreover, the market in the Asia Pacific is expected to show noteworthy growth in the market. Countries such as China and India are the emerging markets for cardiac biomarkers owing to the increasing incidence of coronary artery diseases in these regions. Also, favorable government initiatives to establish modern healthcare facilities are projected to lift the growth of the cardiac biomarkers market in this region.
Cardiac Biomarkers Market, Key Players
· Abbott Laboratories
· Beckman Coulter, Inc.
· bioMérieux SA
· Johnson and Johnson
· Olympus Corporation
· Siemens Healthcare GmbH
· F. Hoffmann-La Roche Ltd.
· PerkinElmer Inc.
· Tosoh Corporation
· Roche Diagnostics
· Becton, Dickinson and Company
· Bio-Rad Laboratories
· Randox laboratories
· Thermo Fisher Scientific
Cardiac Biomarkers Market Segmentation
Cardiac Biomarkers Market, By Type
· Creatine Kinase (CK-MB)
· Troponins T and I
· Myoglobin
· B-Type Natriuretic Peptide (BNPs)
· N-Terminal pro B-type Natriuretic Peptide (NT-proBNP)
· Ischemia-Modified Albumin (IMA)
· Others
Cardiac Biomarkers Market, By Application
· Congestive Heart Failure
· Myocardial Infarction
· Acute Coronary Syndrome
· Atherosclerosis
· Others
Cardiac Biomarkers Market, By Region
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Key Emerging Trends – For Major Countries
- 4.2. Latest Technological Advancement
- 4.3. Regulatory Landscape
- 4.4. Industry SWOT Analysis
- 4.5. Porters Five Forces Analysis
5. Global Cardiac Biomarkers Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Type
- 5.2.1. Creatine Kinase (CK-MB)
- 5.2.2. Troponins T and I
- 5.2.3. Myoglobin
- 5.2.4. B-Type Natriuretic Peptide (BNPs)
- 5.2.5. N-Terminal pro B-type Natriuretic Peptide (NT-proBNP)
- 5.2.6. Ischemia-Modified Albumin (IMA)
- 5.2.7. Others
- 5.3. Market Analysis, Insights and Forecast – By Application
- 5.3.1. Congestive Heart Failure
- 5.3.2. Myocardial Infarction
- 5.3.3. Acute Coronary Syndrome
- 5.3.4. Atherosclerosis
- 5.3.5. Others
- 5.4. Market Analysis, Insights and Forecast – By Region
- 5.4.1. North America
- 5.4.2. Latin America
- 5.4.3. Europe
- 5.4.4. Asia Pacific
- 5.4.5. Middle East and Africa
6. North America Cardiac Biomarkers Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast – By Type
- 6.2.1. Creatine Kinase (CK-MB)
- 6.2.2. Troponins T and I
- 6.2.3. Myoglobin
- 6.2.4. B-Type Natriuretic Peptide (BNPs)
- 6.2.5. N-Terminal pro B-type Natriuretic Peptide (NT-proBNP)
- 6.2.6. Ischemia-Modified Albumin (IMA)
- 6.2.7. Others
- 6.3. Market Analysis, Insights and Forecast – By Application
- 6.3.1. Congestive Heart Failure
- 6.3.2. Myocardial Infarction
- 6.3.3. Acute Coronary Syndrome
- 6.3.4. Atherosclerosis
- 6.3.5. Others
- 6.4. Market Analysis, Insights and Forecast – By Country
- 6.4.1. U.S.
- 6.4.2. Canada
7. Latin America Cardiac Biomarkers Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast – By Type
- 7.2.1. Creatine Kinase (CK-MB)
- 7.2.2. Troponins T and I
- 7.2.3. Myoglobin
- 7.2.4. B-Type Natriuretic Peptide (BNPs)
- 7.2.5. N-Terminal pro B-type Natriuretic Peptide (NT-proBNP)
- 7.2.6. Ischemia-Modified Albumin (IMA)
- 7.2.7. Others
- 7.3. Market Analysis, Insights and Forecast – By Application
- 7.3.1. Congestive Heart Failure
- 7.3.2. Myocardial Infarction
- 7.3.3. Acute Coronary Syndrome
- 7.3.4. Atherosclerosis
- 7.3.5. Others
- 7.4. Market Analysis, Insights and Forecast – By Country
- 7.4.1. Brazil
- 7.4.2. Mexico
- 7.4.3. Rest of Latin America
8. Europe Cardiac Biomarkers Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast – By Type
- 8.2.1. Creatine Kinase (CK-MB)
- 8.2.2. Troponins T and I
- 8.2.3. Myoglobin
- 8.2.4. B-Type Natriuretic Peptide (BNPs)
- 8.2.5. N-Terminal pro B-type Natriuretic Peptide (NT-proBNP)
- 8.2.6. Ischemia-Modified Albumin (IMA)
- 8.2.7. Others
- 8.3. Market Analysis, Insights and Forecast – By Application
- 8.3.1. Congestive Heart Failure
- 8.3.2. Myocardial Infarction
- 8.3.3. Acute Coronary Syndrome
- 8.3.4. Atherosclerosis
- 8.3.5. Others
- 8.4. Market Analysis, Insights and Forecast – By Country
- 8.4.1. UK
- 8.4.2. Germany
- 8.4.3. France
- 8.4.4. Italy
- 8.4.5. Spain
- 8.4.6. Russia
- 8.4.7. Rest of Europe
9. Asia Pacific Cardiac Biomarkers Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 9.1. Key Findings / Summary
- 9.2. Market Analysis, Insights and Forecast – By Type
- 9.2.1. Creatine Kinase (CK-MB)
- 9.2.2. Troponins T and I
- 9.2.3. Myoglobin
- 9.2.4. B-Type Natriuretic Peptide (BNPs)
- 9.2.5. N-Terminal pro B-type Natriuretic Peptide (NT-proBNP)
- 9.2.6. Ischemia-Modified Albumin (IMA)
- 9.2.7. Others
- 9.3. Market Analysis, Insights and Forecast – By Application
- 9.3.1. Congestive Heart Failure
- 9.3.2. Myocardial Infarction
- 9.3.3. Acute Coronary Syndrome
- 9.3.4. Atherosclerosis
- 9.3.5. Others
- 9.4. Market Analysis, Insights and Forecast – By Country
- 9.4.1. China
- 9.4.2. India
- 9.4.3. Japan
- 9.4.4. Australia
- 9.4.5. South East Asia
- 9.4.6. Rest of Asia Pacific
10. Middle East & Africa Cardiac Biomarkers Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 10.1. Key Findings / Summary
- 10.2. Market Analysis, Insights and Forecast – By Type
- 10.2.1. Creatine Kinase (CK-MB)
- 10.2.2. Troponins T and I
- 10.2.3. Myoglobin
- 10.2.4. B-Type Natriuretic Peptide (BNPs)
- 10.2.5. N-Terminal pro B-type Natriuretic Peptide (NT-proBNP)
- 10.2.6. Ischemia-Modified Albumin (IMA)
- 10.2.7. Others
- 10.3. Market Analysis, Insights and Forecast – By Application
- 10.3.1. Congestive Heart Failure
- 10.3.2. Myocardial Infarction
- 10.3.3. Acute Coronary Syndrome
- 10.3.4. Atherosclerosis
- 10.3.5. Others
- 10.4. Market Analysis, Insights and Forecast – By Country
- 10.4.1. GCC
- 10.4.2. South Africa
- 10.4.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Company Market Share Analysis, 2018
- 11.2. Key Industry Developments
- 11.3. Company Profile
- 11.4. Abbott Laboratories
- 11.4.1. Business Overview
- 11.4.2. Segment 1 & Service Offering
- 11.4.3. Overall Revenue
- 11.4.4. Geographic Presence
- 11.4.5. Recent Development
- 11.5. Beckman Coulter, Inc.
- 11.6. bioMérieux SA
- 11.7. Johnson and Johnson
- 11.8. Olympus Corporation
- 11.9. Siemens Healthcare GmbH
- 11.10. F. Hoffmann-La Roche Ltd.
- 11.11. PerkinElmer Inc.
- 11.12. Tosoh Corporation
- 11.13. Roche Diagnostics
- 11.14. Becton, Dickinson and Company
- 11.15. Bio-Rad Laboratories
- 11.16. Randox laboratories
Data Library Research are conducted by industry experts who offer insight on industry structure, market segmentations technology assessment and competitive landscape (CL), and penetration, as well as on emerging trends. Their analysis is based on primary interviews (~ 80%) and secondary research (~ 20%) as well as years of professional expertise in their respective industries. Adding to this, by analysing historical trends and current market positions, our analysts predict where the market will be headed for the next five years. Furthermore, the varying trends of segment & categories geographically presented are also studied and the estimated based on the primary & secondary research.
In this particular report from the supply side Data Library Research has conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and SOFT) of the companies that active & prominent as well as the midsized organization
FIGURE 1: DLR RESEARH PROCESS
Extensive primary research was conducted to gain a deeper insight of the market and industry performance. The analysis is based on both primary and secondary research as well as years of professional expertise in the respective industries.
In addition to analysing current and historical trends, our analysts predict where the market is headed over the next five years.
It varies by segment for these categories geographically presented in the list of market tables. Speaking about this particular report we have conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market.
Secondary ResearchSecondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and Friend’s study of the Global Extra Neutral Alcohol. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and technology perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, sec filings, journals, white papers, SOFT presentations, and company web sites.
Market Size EstimationBoth, top-down and bottom-up approaches were used to estimate and validate the size of the Global market and to estimate the size of various other dependent submarkets in the overall Extra Neutral Alcohol. The key players in the market were identified through secondary research and their market contributions in the respective geographies were determined through primary and secondary research.
Forecast Model
